Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Foghorn Therapeutics Inc. (FHTX) reported a Q3 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates.
November 05, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Foghorn Therapeutics reported a Q3 loss of $0.31 per share, better than the expected $0.42 loss, but missed revenue estimates. This mixed result may lead to short-term stock price volatility.
The better-than-expected EPS loss is a positive sign, but missing revenue estimates could offset this, leading to potential short-term volatility in FHTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100